Growing competition across the globe, clinical attrition, the complexity and costs of drug development and manufacturing, are all factors that impact today’s pharmaceutical industry.
As biologics continue to grow as a target area of research, pharmaceutical firms continue to develop creative strategies to advance their small molecule pipeline through clinical development.
The growth in outsourcing is one strategy life science innovators are pursuing to address this evolving landscape; however, should a sponsor company seek the traditional route of utilising multiple partners across the supply chain or does an integrated CDMO offer a more efficient and faster path to commercialisation?
